Data generated from in vitro assays and preclinical HF models provide strong evidence that modulating cMyBP-C and, consequently, its phosphorylation status, increases ATPase activity and force kinetics in a manner that improves overall cardiac performance. The gene discussed is MYBPC3; the disease is hydrops fetalis.